{"analyses":[{"ciLowerLimit":"0.525","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.052","groupDescription":"bTMB \\>=10-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.743"},{"ciLowerLimit":"0.331","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.924","groupDescription":"bTMB \\>=16-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.553"},{"ciLowerLimit":"0.295","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.062","groupDescription":"bTMB \\>=20-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.560"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"5.4","value":"4.3"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"6.8","value":"5.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"bTMB >=10-WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"5.7","value":"4.4"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"11.6","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"bTMB >=16-WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"6.4","value":"5.2"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"17.2","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"bTMB >=20-WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"PFS according to RECIST v1.1 in the bTMB subpopulations.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"},{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG001","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed for participants with bTMB \\>=10 Intent-to-treat Wild Type Population.","reportingStatus":"POSTED","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","title":"Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Months"}